Dr. Santa-Maria completed his oncology training at Johns Hopkins, and has been focused on caring for patients with breast cancer since then. He works as both a primary oncologist and consultant for patients with all types and stages of breast cancer. His research interest is in developing new types of treatment for patients with breast cancer using immunotherapy. Dr. Santa is rated as a Distinguished provider by MediFind in the treatment of Triple-Negative Breast Cancer. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, and Paget Disease of the Breast.

Dr. Antonio Wolff is internationally recognized for his work on breast cancer biomarkers, including HER2. As a practicing oncologist and clinical translational researcher, his research has been pivotal to improve the quality of breast cancer biomarker testing in breast cancer, including HER2 and estrogen receptor testing. Among his leadership accomplishments is ensuring that sophisticated laboratory findings are translated into improved clinical care in breast cancer. He is a Fellow of the American Society of Clinical Oncology (ASCO), a Komen Scholar and a Breast Cancer Research Foundation investigator. He has served as associate editor for Journal of Clinical Oncology, and serves on the National Comprehensive Cancer Network (NCCN) Guideline Steering Committee. He is a leader of the Translational Breast Cancer Research Consortium (TBCRC), and one of the principal investigators of the Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (EVOLVE) in Metastatic Breast Cancer, which was one of the three disease groups recently awarded by ARPA-H to conduct innovative trials using Advanced Analysis for Precision Cancer Therapy (ADAPT). After many years of service as Breast Committee Chair in the ECOG-ACRIN Clinical Trial Network of the National Cancer Institute (NCI), he was elected in 2024 as Co-Chair of the NCI Breast Cancer Steering Committee and appointed to the international steering committee of the Oxford Overview Collaborative, which are positions aimed at advancing clinical trials in breast cancer. At Johns Hopkins, he is an elected member of the Miller Coulson Academy of Clinical Excellence and was honored during the 125th Anniversary Living the Hopkins Mission celebrations of the JHU School of Medicine. Dr. Wolff is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. His top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Triple-Negative Breast Cancer, and Inflammatory Breast Cancer.

William Houck is an Oncologist in Baltimore, Maryland. Dr. Houck is rated as an Advanced provider by MediFind in the treatment of Triple-Negative Breast Cancer. His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Chronic B-Cell Leukemia (CBCL), and Chronic Lymphocytic Leukemia (CLL).

Dr. Kristin Redmond specializes in the treatment of brain tumors and leads the spinal radiosurgery program. She received her undergraduate degree from Princeton University where she graduated magna cum laude with a focus in neuro-psychology. She attended medical school and obtained a Masters in Public Health in health systems management at Tulane University where she was elected to the Alpha Omega Alpha Honor Medical Society as well as the Gold Humanism in Medicine Honor Society. Dr. Redmonds research interest focuses on the development of novel radiation techniques and therapeutic agents to treat brain and spine tumors in order to increase tumor control and overall survival. In addition, she is working to develop innovative approaches to try to limit long term toxicities and minimize neuro-cognitive dysfunction following treatment for tumors of the central nervous system. Dr. Redmond believes in a holistic approach to medicine and feels that the social and psychological components of patient care are equally important to traditional therapies. She works closely with a team of specialists to support patients and families during their cancer journey. Make A Gift. Dr. Redmond is rated as an Advanced provider by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Chordoma, Brain Tumor, Astrocytoma, and Metastatic Brain Tumor.

Dr. Kleinberg specializes in the radiation treatments, including stereotactic radiosurgery, of brain and spinal tumors. Areas of research include both tumors arising in the central nervous system and tumors metastasizing from other locations. He also specializes in the treatment of esophageal tumors and has led national clinical trials in both therapy of brain tumors as well as esophageal cancer. Dr. Kleinberg has been recently named in the US News and World Report list of top 1% of doctors in his specialty. He is the co-chair of the Eastern Cooperative Oncology Group Brain Tumor Working Group, Vice-Chair of the NCI Cooperative Group Steering Committee for Esophageal and Gastric Tumors, and is a member of the NCI Cooperative Group Steering Committee for Gastrointestinal Tumors. He is also on the American College of Radiation Oncology Neurologic Cancer Practice Accreditation Team. Make A Gift. Dr. Kleinberg is rated as an Advanced provider by MediFind in the treatment of Triple-Negative Breast Cancer. His top areas of expertise are Glioblastoma, Astrocytoma, Brain Tumor, Hepato-Pancreato-Biliary Surgery, and Gamma Knife Radiosurgery.

Stéphanie Gaillard is a medical oncologist who specializes in the treatment of gynecologic malignancies. She recently joined the faculty of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and is their Director of Gynecologic Cancer Trials. Dr. Gaillard earned her medical degree and doctoral degree in cancer biology from Duke University. Following medical school, she underwent residency training in Internal Medicine and fellowship training in Medical Oncology at the Johns Hopkins School of Medicine. Dr. Gaillard’s research focuses on the development of clinical trials aimed at improving outcomes by incorporating promising new biologic, targeted, and immune therapies into standard treatment regimens. Her translational research program focuses on understanding the immune environment associated with gynecologic cancers and mechanisms of resistance to current therapies. Dr. Gaillard is rated as an Advanced provider by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Tissue Biopsy, and Salpingo-Oophorectomy.

Leisha Emens is an Oncologist in Baltimore, Maryland. Dr. Emens is rated as a Distinguished provider by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, and Ovarian Cancer.

Noeline Rajarajan is a General Surgeon in Baltimore, Maryland. Dr. Rajarajan is rated as an Experienced provider by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Breast Lump, and Intraductal Papilloma. Dr. Rajarajan is currently accepting new patients.

Takeo Fujii is an Oncologist in Baltimore, Maryland. Dr. Fujii is rated as an Advanced provider by MediFind in the treatment of Triple-Negative Breast Cancer. His top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Triple-Negative Breast Cancer, and Bone Tumor.

Ravin Garg is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Garg is rated as an Advanced provider by MediFind in the treatment of Triple-Negative Breast Cancer. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Paget Disease of the Breast, Breast Cancer, and Thrombotic Thrombocytopenic Purpura.

Dr. Kenneth Pienta is the Donald S. Coffey Professor of Urology and a professor of oncology at the Johns Hopkins School of Medicine. He also holds an appointment in the department of pharmacology and molecular sciences. He is an internationally recognized leader in prostate cancer research and translational science. Dr. Pienta serves as the director of research for the Brady Urological Institute and co-leader of the Kimmel Cancer Center's Prostate Cancer Program. Dr. Pienta has a proven, peer-reviewed track record in organizing and administering a translational research program that successfully incorporates bench research, agent development and clinical application. He has international expertise in the development of novel chemotherapeutic programs for prostate cancer and has championed the concept that translational research is often best accomplished by multi-disciplinary teams of scientists and clinicians. Under his direction, the success of these endeavors led to the receipt of the first annual American Association for Cancer Research Team Science Award in 2007. Dr. Pienta received his B.A. in human biology from the Johns Hopkins University. He earned his M.D. from the Johns Hopkins School of Medicine. He completed his residency at the University of Chicago Hospitals and Clinics and performed a fellowship in oncology at The Johns Hopkins Hospital. Prior to joining Johns Hopkins, Dr. Pienta was the associate vice president for research, health sciences for the University of the Michigan from 2012 to 2013 and director of precision medicine for the Michigan Center for Translational Pathology from 2008 to 2013. He joined the Johns Hopkins faculty in 2013. Dr. Pienta's research interests include the ecology of cancer, tumor microenvironment, metastasis, biomarker development and novel therapeutic development. Dr. Pienta is a two-time American Cancer Society Clinical Research Professor Award recipient. He holds several patents, has authored more than 350 peer-reviewed articles and has been the principle investigator on numerous local and national clinical trials. Dr. Pienta is currently actively developing clinical trials and treating patients with newly diagnosed high risk and metastatic prostate cancer. Dr. Pienta is rated as an Experienced provider by MediFind in the treatment of Triple-Negative Breast Cancer. His top areas of expertise are Prostate Cancer, Bone Tumor, Familial Prostate Cancer, Prostatectomy, and Orchiectomy.

Padma Rajagopal is an Oncologist in Baltimore, Maryland. Dr. Rajagopal is rated as an Experienced provider by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Familial Prostate Cancer, Triple-Negative Breast Cancer, Autoimmune Hemolytic Anemia, and Gastrostomy.

Dr. Jessica Tao is a medical oncologist specializing in the care of patients with breast cancer. She co-leads the Cancer Center-wide Johns Hopkins Molecular Tumor Board, a multidisciplinary effort to interpret complex genomic information and provide individualized, precision oncology treatment recommendations to patients with all types of cancer. In addition to caring for patients, Dr. Tao maintains an active clinical-translational research program dedicated to developing novel treatments to patients with advanced cancer. Her expertise and research focuses on finding and targeting the molecular changes that drive a person’s tumor and understanding novel mechanisms of response and resistance to targeted therapies. A second major area of her research is development and application of “liquid biopsy” technologies, including circulating tumor DNA, in the early detection and disease monitoring of breast cancer. Dr. Tao is rated as an Experienced provider by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and Angiosarcoma.

Tatiana M. Prowell, MD is Associate Professor of Oncology in the Division of Women's Malignancies at the Johns Hopkins Kimmel Comprehensive Cancer Center and Breast Cancer Scientific Liaison to the U.S. Food and Drug Administration. She was the principal architect of FDA’s policy on accelerated approval using pathological complete response as a novel regulatory endpoint in the neoadjuvant high-risk breast cancer setting, and a member of the Biden Cancer Moonshot Blue Ribbon Panel Cancer Immunology Working Group. A frequent public speaker, she is a three-time recipient of FDA’s Excellence in Communication Award. She is a past Giants of Cancer Care Award finalist, the recipient of the 2019 John and Samuel Bard Medal in Science or Medicine, and the recipient of a 2020 Webby Special Achievement Award for her effective use of social media during the pandemic. A passionate medical educator and mentor, she was Chair of the 2020 ASCO Annual Meeting Education Committee and has served for many years on the faculty of the Vail ASCO/AACR Methods in Clinical Cancer Research Workshop, the Society for Translational Oncology Fellows’ Forum, the Dana Farber Clinical Investigator Seminar Series, and the FDA-ASCO Fellows’ Day Workshop, among several others. Dr. Prowell staffs the second opinion breast cancer clinic and teaches in the Johns Hopkins School of Medicine MD/PhD medical ethics course and the medical oncology fellowship training program. Her areas of particular clinical and research interest include development of novel agents for breast cancer, neoadjuvant therapy for breast cancer, brain metastases, decentralized clinical trials, and the unique challenges of breast cancer in younger women. Dr. Prowell received her BA degree from Bard College in literature and her MD degree from the Johns Hopkins School of Medicine with election to the Phi Beta Kappa and Alpha Omega Alpha honor societies. She completed her residency and fellowship training at Johns Hopkins Hospital. She tweets as @tmprowell about cancer, public health, COVID-19, medical education, health equity, and women in medicine. Dr. Prowell is rated as an Experienced provider by MediFind in the treatment of Triple-Negative Breast Cancer. Her top area of expertise is Triple-Negative Breast Cancer.

Dr. Susan Bahl, MD, FACS, is a distinguished Breast Surgeon who recently joined Johns Hopkins, practicing at both Howard County Medical Center and Johns Hopkins Bayview Medical Center. A strong advocate for women's health, Dr. Bahl brings over a decade of experience in providing state-of-the-art, evidence-based breast care within multidisciplinary settings. She has a passion for delivering personalized treatment plans to patients, specializing in both benign and malignant breast diseases. Before joining Johns Hopkins, Dr. Bahl served as the Medical Director of the Frederick Health Breast Center, where she founded a NAPBC-accredited multidisciplinary breast cancer clinic. In this role, she helped streamline the treatment process for newly diagnosed breast cancer patients by coordinating care between breast surgeons, medical oncologists, and radiation oncologists. Dr. Bahl also co-directed a Breast Screening and Prevention Program designed for high-risk women, integrating genetic testing, risk-reduction surgeries, and chemo-prevention strategies. Her commitment to patient-centered care and leadership in breast health make her a valuable addition to the Johns Hopkins community. Dr. Bahl is rated as an Experienced provider by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, Inflammatory Breast Cancer, and Lymphadenectomy.

Elizabeth Nichols is a Radiation Oncologist in Baltimore, Maryland. Dr. Nichols is rated as an Experienced provider by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Angiosarcoma, Cervical Cancer, and Adult Soft Tissue Sarcoma.

Jason Molitoris is a Radiologist and a Radiation Oncologist in Baltimore, Maryland. Dr. Molitoris is rated as an Experienced provider by MediFind in the treatment of Triple-Negative Breast Cancer. His top areas of expertise are Prostate Cancer, Adult Soft Tissue Sarcoma, Familial Prostate Cancer, Anal Cancer, and Gastrostomy.

Roisin Connolly is an Oncologist in Baltimore, Maryland. Dr. Connolly is rated as an Advanced provider by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Tissue Biopsy.

Elizabeth Jaffee is an Oncologist in Baltimore, Maryland. Dr. Jaffee is rated as an Advanced provider by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Fibrolamellar Carcinoma, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery.

Katherine Tkaczuk is an Oncologist in Baltimore, Maryland. Dr. Tkaczuk is rated as an Advanced provider by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, and Paget Disease of the Breast. Dr. Tkaczuk is currently accepting new patients.